Is Coke Zero Bad for You?
Coke Zero is calorie-free but has no nutritional value. While drinks with artificial sweeteners may have negative long-term effects, such as increasing the risk of type 2 diabetes, more research is needed.
Coke Zero, recently rebranded as Coca-Cola Zero Sugar, is marketed as a healthier version of the original sugar-sweetened beverage, Coca-Cola Classic.
It contains zero calories and sugar while providing the signature Coca-Cola flavor, appealing to those trying to reduce their sugar intake or control their weight.
This article takes a detailed look at Coke Zero and explains whether it's a healthy choice.
Zero nutritional value
Coke Zero does not provide any calories and is not a significant source of nutrition.
One 12-ounce (354-ml) can of Coca-Cola Zero Sugar (Coke Zero) offers:
Calories: 0
Fat: 0 grams
Protein: 0 grams
Sugar: 0 grams
Sodium: 2% of the Daily Value (DV)
Potassium: 2% of the DV
Artificial sweeteners are used to sweeten this beverage without adding calories.
The health effects of artificial sweeteners are controversial, and concerns regarding their safety are growing.
Though the research is inconsistent, some studies find that the use of artificial sweeteners may contribute to the development of obesity and metabolic syndrome, a cluster of conditions that increase disease risk.
Coca-Cola Zero Sugar (Coke Zero) uses several common artificial sweeteners, including aspartame and acesulfame potassium (Ace-K). The remaining ingredients are carbonated water, caramel color, food additives, and natural flavors.
The only differences between Coke Zero and the new rebrand Coca-Cola Zero Sugar are minor changes to the natural flavor composition.
Artificial sweeteners and weight loss
Research results on the effects of Coke Zero and other artificially sweetened beverages on weight loss are mixed.
In a 2023 52-week study of 493 adults, researchers found that compared to people who drank water, those who consumed beverages with non-nutritive sweeteners lost more weight over the study period, an average of 16.5 pounds (7.5 kilograms), compared to those who drank water, who lost an average of 13.4 pounds (6.1 kg).
However, a similar 2023 study that lasted 12 weeks found no difference in weight loss among participants who drank water versus beverages with non-nutritive sweeteners. The researchers also examined other metrics, like waist circumference, but found no significant differences. The non-nutritive sweetener group lost slightly more to their waist circumference, but the difference was about 1 centimeter (cm).
A 2023 review of research that looked at multiple studies suggests that non-nutritive sweeteners have no immediate effects on the metabolic or endocrine systems.
The evidence on the effects of artificially sweetened beverages on weight management is conflicting, and more research is needed. Long-term research is also needed to determine if artificial sweeteners may influence the body in ways other than calorie intake.
Diet sodas and tooth erosion
Similarly to regular soda, drinking diet sodas like Coke Zero is associated with an increased risk of tooth erosion.
One of the main ingredients in Coke Zero is phosphoric acid.
One 2002 study on human teeth noted phosphoric acid causes mild enamel and tooth erosion.
An older study from 2015 observed that Coca-Cola Light (Diet Coke), which differs from Coke Zero only in that it contains both phosphoric and citric acid, caused enamel and tooth erosion in freshly extracted cow's teeth in just 3 minutes.
Still, the same 2002 study suggests that citric acid erodes teeth more than phosphoric acid, which suggests that Coke Zero may affect tooth enamel slightly less than Diet Coke.
Diet Coke had less erosive effects than other beverages, such as Sprite, orange juice, and apple juice.
Coke Zero and diabetes risk
Coke Zero is sugar-free. However, the sugar substitutes it contains may not necessarily be a better option for people looking to reduce their risk of diabetes.
A large 2023 study involving 105,588 participants with a follow-up of 9.1 years suggests that consuming non-nutritive sweeteners is associated with an increased risk of developing type 2 diabetes.
A 2024 review of research suggests non-nutritive sweeteners may negatively affect the gut microbiome, or the helpful bacteria that live in your gut and aid digestion, potentially affecting metabolic health and contributing to diabetes risk and worse outcomes for people with diabetes.
The results from these studies don't provide an exact explanation of how artificially sweetened beverages increase your risk of diabetes. Therefore, more research is needed.
Other potential downsides
Artificially sweetened beverages like Coke Zero have been linked to other health issues, including:
Increased risk of heart disease: An observational study found a link between artificially sweetened beverages and an increased risk of heart disease among women with no prior history of heart disease.
Increased risk of kidney disease: Soda's high phosphorus content may damage kidneys. A 2017 study noted that those who drink more than 7 glasses of diet soda per week nearly double their risk of kidney disease.
Could alter your gut microbiome: Artificially sweetened beverages may alter your gut microbiome, potentially negatively affecting blood sugar management.
Further research is needed to determine the exact effects of Coke Zero and other diet beverages on your health.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
U.S. Supreme Court orders review over religious challenge to New York abortion law
The U.S. Supreme Court on Monday ordered a lower court in New York to reevaluate whether some religious organizations should be excluded from a state mandate that requires employers to provide employee health care plans that include abortion coverage. The ruling from the high court said the case, Diocese of Albany v. Harris, should be sent back to New York courts to be reviewed again in light of an earlier unanimous Wisconsin case related to the Catholic Church groups being denied state tax exemptions. The justices pointed to the Wisconsin case because the New York case poses similar issues about states exempting religious employers and faith-based groups, The Associated Press reported. The New York case stems from a 2017 state mandate that requires health insurance plans provided by employers to include abortion coverage for situations that include rape and incest. The state mandate includes a religious exemption for institutions, but not for religious-affiliated groups. It was challenged by Catholic and Anglican nuns, Catholic dioceses, Christian churches and other faith organizations. They argued the religious exemption is so narrow that it violates the freedom of religion protected under the First Amendment. The most recent order from the Supreme Court is the second time the case has reached the justices after being litigated for years. After the state adopted the mandate in 2017, religious groups challenged it in state court. The appeals court upheld the regulation and the state refused to exempt religious organizations. In 2021, the religious groups appealed the state's ruling to the U.S. Supreme Court. Justices asked New York to reconsider based on its ruling in another case involving religion, Fulton v. Philadelphia. State courts found the Fulton decision was inapplicable to the situation, prompting the groups to bring it to the Supreme Court again. The religious liberty law firm Becket noted in a release that New York's exemption doesn't currently apply to some organizations, including the Carmelite Sisters for the Aged and Infirm and the Teresian Nursing Home because they 'serve the elderly and dying regardless of religious affiliation.' 'New York wants to browbeat nuns into paying for abortions for the great crime of serving all those in need,' Becket Vice President and senior counsel Eric Baxter said in a statement.' Following the Supreme Court's Monday order, the case is headed back to the New York Court of Appeals.
Yahoo
an hour ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
